What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “5 participants will receive SLN12140 100mg QW for 4 weeks, then 300mg QW for 8 weeks, then 200mg QW for 52 weeks. 5 participants will receive SLN12140 200mg QW for 4 weeks, then 600mg Q4W for 60 weeks”In the company’s words, NCT07387302 on ClinicalTrials.gov
- Main trialPhase 2
- “The goal of this clinical trial is to learn if drug SLN12140 works to treat Complement Inhibitor-Naïve Subjects with Paroxysmal Nocturnal Hemoglobinuria in adults. It will also learn about the safety, pharmacokinetic characteristics, and dosing of drug SLN12140. The study is divided into four phases: screening period, core treatment period, extended dosing period, and follow-up period, and includes two cohorts (Cohorts 1-2), with each cohort enrolling at least 5 treatment-naïve adult PNH subjects for complement inhibitor therapy.”In the company’s words, NCT07387302 on ClinicalTrials.gov
Other drugs for Paroxysmal Nocturnal Hemoglobinuria (PNH)
Coming up1
- Dec 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Not yet recruiting | 31 Jul 2026 | SLN12140 in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) in China | |
| Phase 2Not yet recruiting | Dec 2027 | SLN12140 in Adult Participants With IgA Nephropathy in China | |
| Phase 1Not yet recruiting | May 2026 | Study of SLN12140 in Healthy Adult Participants |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026